In the past, pharmaceutical companies were only allowed to hold patents on the process of manufacturing drugs, not on the compounds themselves. This meant that developing countries could produce generic versions of important medicines – and sell them for a fraction of the cost – so long as they were able to find their own methods of manufacturing them. TRIPS put an end to this practice by extending corporate patents down to the level of the molecule itself.
